JP2015505530A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505530A5
JP2015505530A5 JP2014525551A JP2014525551A JP2015505530A5 JP 2015505530 A5 JP2015505530 A5 JP 2015505530A5 JP 2014525551 A JP2014525551 A JP 2014525551A JP 2014525551 A JP2014525551 A JP 2014525551A JP 2015505530 A5 JP2015505530 A5 JP 2015505530A5
Authority
JP
Japan
Prior art keywords
group
compound
cancer
tumor
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014525551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505530A (ja
JP6209516B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/054160 external-priority patent/WO2013024447A1/en
Publication of JP2015505530A publication Critical patent/JP2015505530A/ja
Publication of JP2015505530A5 publication Critical patent/JP2015505530A5/ja
Application granted granted Critical
Publication of JP6209516B2 publication Critical patent/JP6209516B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014525551A 2011-08-18 2012-08-15 癌治療に使用するための化合物 Expired - Fee Related JP6209516B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524826P 2011-08-18 2011-08-18
PCT/IB2012/054160 WO2013024447A1 (en) 2011-08-18 2012-08-15 Compounds for use in cancer therapy

Publications (3)

Publication Number Publication Date
JP2015505530A JP2015505530A (ja) 2015-02-23
JP2015505530A5 true JP2015505530A5 (enExample) 2015-09-17
JP6209516B2 JP6209516B2 (ja) 2017-10-04

Family

ID=47010660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525551A Expired - Fee Related JP6209516B2 (ja) 2011-08-18 2012-08-15 癌治療に使用するための化合物

Country Status (4)

Country Link
US (2) US9878998B2 (enExample)
EP (1) EP2744500A1 (enExample)
JP (1) JP6209516B2 (enExample)
WO (1) WO2013024447A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744500A1 (en) 2011-08-18 2014-06-25 Nuhope LLC Compounds for use in cancer therapy
CN103405437B (zh) * 2013-08-30 2015-01-21 苏州大学 一种pi3k小分子抑制剂及其应用
GB201805386D0 (en) * 2018-03-31 2018-05-16 Opal Oncology Ltd Pharmaeutical compounds
RU2717246C1 (ru) * 2019-06-17 2020-03-19 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ПГФА) Этил 4-(5-бензоил-6-(4-(диэтиламино)фенил)-4-гидрокси-2-тиоксогексагидропиримидин-4-карбоксамино)бензоат, проявляющий анальгетическое и противовоспалительное действие
US20220289981A1 (en) * 2019-08-21 2022-09-15 Regents Of The University Of Minnesota Pigmented and fluorescent compounds derived from the addition of a primary or secondary amine to an aldehyde
CN113292448B (zh) * 2021-06-25 2022-06-28 中山大学 一种茚酮类亚胺衍生物及其制备方法与应用
CN117777030A (zh) * 2023-12-22 2024-03-29 郑州大学 一种粘度响应型发光探针、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418291A1 (en) 1988-06-08 1991-03-27 Eastman Kodak Company Novel merocyanine dyes
GB0013655D0 (en) 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
US20050049267A1 (en) 2002-03-01 2005-03-03 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2005046595A2 (en) * 2003-11-07 2005-05-26 Emory University Hif-1 inhibitors and methods of use thereof
WO2007120842A2 (en) 2006-04-13 2007-10-25 Cornell Research Foundation, Inc. Methods and compositions for targeting c-rel
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
US8309523B2 (en) 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2744500A1 (en) 2011-08-18 2014-06-25 Nuhope LLC Compounds for use in cancer therapy

Similar Documents

Publication Publication Date Title
JP2015505530A5 (enExample)
RU2019118460A (ru) Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение
JP2019516766A5 (enExample)
JP2011520770A5 (enExample)
JP2013544847A5 (enExample)
JP2014500870A5 (enExample)
EA201290210A1 (ru) Соединения и способы модуляции киназы и показания для их применения
JP2016504325A5 (enExample)
RU2017114687A (ru) Ингибитор egfr и его получение и применение
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2012153722A5 (enExample)
JP2017537114A5 (enExample)
RU2016107884A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2018138584A (ru) Соединения-ингибиторы egfr
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
MX2012013274A (es) Novedosos derivados de la pirimidina.
JP2014530811A5 (enExample)
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2009504771A5 (enExample)
JP2016534048A5 (enExample)
WO2014141057A3 (en) Compositions and methods for the treatment of cancer
RU2017129151A (ru) Производное резорцина в качестве ингибитора hsp90
CN116157128A (zh) 吡唑并哒嗪酮化合物、其药物组合物及其用途
JP2015502371A5 (enExample)